en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">this study focused on evaluating the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with cervical cancer (CC) undergoing neoadjuvant chemotherapy and radiation therapy. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods:</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> a total of 58 CC patients were included, undergoing examination through DCE-MRI scans. Subsequently, all cases were divided into two groups: the chemotherapy-effective group (32 cases) including complete response (CR) and partial response (PR), and the chemotherapy-ineffective group (26 cases) including stable disease (SD) and disease progression (PD). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">after treatment, the average maximum diameter of tumors in the chemotherapy and radiation therapy failure group was 4.38 &plusmn; 1.23 cm, drastically larger than the 2.51&plusmn;0.64 cm in the chemotherapy and radiation therapy response group (P < 0.05). Before treatment, the K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> of the chemotherapy and radiation therapy response group was superior to that of the failure group, while Ve was inferior to the latter (P < 0.05). After treatment, the K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> of the chemotherapy and radiation therapy response group decreased, showing a more drastic reduction compared to the failure group (P < 0.05). The K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> of the chemotherapy and radiation therapy response group was drastically inferior to that of the failure group, with statistical significance (P<0.05). The </span></span></span><span lang="el" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:el">&Delta;</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">% in the chemotherapy and radiation therapy response group was negative, inferior to pre-treatment values. In contrast, the </span></span></span><span lang="el" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:el">&Delta;</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">% in the chemotherapy and radiation therapy failure group was positive, superior to pre-treatment values (P < 0.05). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">DCE-MRI demonstrates excellent scanning performance for CC, accurately monitoring the blood flow signals of CC tumors. K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">, Ve, and </span></span></span><span lang="el" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:el">&Delta;</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">K</span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">^trans</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> have high predictive value in neoadjuvant chemotherapy and radiation therapy.</span></span></span></span></span></span></span></span></span></div> dynamic contrast-enhanced magnetic resonance imaging, quantitative parameters, cervical cancer, neoadjuvant chemotherapy, efficacy evaluation. 1067 1074 http://ijrr.com/browse.php?a_code=A-10-1-1277&slc_lang=en&sid=1 M. Yi 7900319475328460028829 7900319475328460028829 No Department of Radiology, Chongqing Fifth People's Hospital, Chongqing, 400062, China R. Hong 7900319475328460028830 7900319475328460028830 No Department of Ultrasound, Affiliated Cancer Hospital of Chongqing University, Chongqing, 400030, China Zh. Zhang 7900319475328460028831 7900319475328460028831 No Department of Radiology, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, 710000, Shaanxi, China Z. Xiong 7900319475328460028832 7900319475328460028832 No Department of Radiology, Chongqing Fifth People's Hospital, Chongqing, 400062, China J. Ran songxundou32875378@163.com 7900319475328460028833 7900319475328460028833 Yes Department of Radiology, Chongqing Fifth People's Hospital, Chongqing, 400062, China